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Editorial: the increasing burden of microscopic colitis
Microscopic colitis (MC) is a worldwide emergent cause of watery 
chronic diarrhoea in adults.1,2 Initially considered a rare disease, sev‐
eral epidemiological studies reported an increasing incidence over 
time with similar incidence rate of Crohn's disease or ulcerative coli‐
tis, especially in women and elderly patients.3,4 However, both re‐
gional 3,4 and nationwide 5‐7 studies have often shown heterogenous 
results in terms of incidence rate, trends and distribution among 
collagenous colitis (CC) and lymphocytic colitis (LC), the two main 
subtypes of MC (Table 1).
In a recent issue, Bergman et al explore the incidence rate of MC 
in Sweden over a 20‐year period using a national pathology registry 
with combination of clinical data.8 Notably, this registry was previ‐
ously validated performing a retrospective review of the medical 
charts of 215 randomly selected MC pathology records from 15 pa‐
thology departments.9 Although this validation process involved a 
small subset of MC incident cases (0.07%) from five counties, the 
resulting 95% positive predictive value represents a unique and solid 
basis to minimise the risk of false positive diagnosis and reliably esti‐
mate the real incidence of MC in Sweden.9
Consistent with two recent nationwide cohort studies from 
Denmark6 and the Netherlands,7 the study from Bergman et al con‐
firms the MC incidence rise also in Sweden (up to 10.7 cases/100 000 
person‐years).8 The Swedish study, however, has a longer follow‐up 
(20 years, 1995‐2015) revealing a stabilising trend in recent years.8 
Interestingly, two consecutive population‐based studies from the 
Olmsted County in 1985‐2001 and 2002‐201010 described the same 
plateau effect. The spread of MC‐related risk factors, together with 
an ameliorated access to colonoscopy, number of colonic biopsies 
and clinical awareness are regarded as the main drivers of this figure.
A predominance for the LC subtype was found in Bergman et 
al study, in accordance with pooled incidence rate reported in a 
previous meta‐analysis.3 On the contrary, the three previous na‐
tionwide studies from Iceland,5 Denmark6 and the Netherlands7 as 
well as other regional or local studies in Sweden3,10 contradict this. 
Resolving this apparent discrepancy remains an unresolved research 
question. There is a risk of misclassification between the two main 
subtypes due to: patchy distribution of the thickened collagen band 
compared with the more general increase in the intraepithelial lym‐
phocyte count8; variation in pathologists' practice and histological 
stains applied, especially in borderline cases1; no homogeneous pre‐
defined diagnostic protocol (number of biopsies or other explora‐
tions to rule out other diagnosis); and other genetic or environmental 
influencing factors.
Well‐designed epidemiological and case‐control studies are still 
necessary to determine the precise burden of MC and of its two 
main subtypes (CC and LC) worldwide. Nonetheless, the clinical 
perception of MC is remarkably changed 40 years after their dis‐
covery. In 2019, the sum of evidence requires us to think about MC, 
consider it during colonoscopy and always take biopsies throughout 
the colon.
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First author 
(year) Country/city
MC incidence 
(95% CI)
CC incidence 
(95% CI)
LC incidence 
(95% CI)
Nationwide studies
Agnarsdottir 
(2002)
Iceland NA 5.2 (4.1‐6.6) 4 (3‐5.2)
Agnarsdottir 
(2002)
Denmark 4.6‐24.7a 2.9‐14.9 (NA)a 1.7‐9.8 (NA)a
Agnarsdottir 
(2002)
The Netherlands 3.4 (3.3‐3.5) 1.8 (1.7‐1.8) 1.3 (1.2‐1.3)
Agnarsdottir 
(2002)
Sweden 7.2 (5.6‐8.7) NA NA
Swedish studies
Bohr (1995) Örebro NA 1.8 (1.2‐2.4) NA
Olesen (2004) Örebro NA 4.9 (3.6‐6.2) 4.4 (3.1‐5.7)
Vigren (2012) Skane NA 5.4 (4.3‐6.5) NA
Thorn (2013) Uppsala NA 7 (NA) 4.8 (NA)
Wickbom 
(2013)
Örebro 10.2 (8.7‐11.7) 5.2 (4.2‐6.3) 5 (4‐6)
Davidson 
(2018)
Skane NA 5.9 (4.6‐7.3) 2.7 (1‐4.3)
Abbreviation: NA, not available.
aIncidence rate of MC, CC and LC in 2002 and 2011 years. 
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